References
Original article
Baas, P. et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 397, 375–386 (2021)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Romero, D. Benefit with first-line ICIs in mesothelioma. Nat Rev Clin Oncol 18, 194 (2021). https://doi.org/10.1038/s41571-021-00481-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-021-00481-5
- Springer Nature Limited